Ocular surface stem cell transplantation (OSST) patients should be closely monitored for rejection and compliance with immunosuppression.
Ocular surface stem cell transplantation (OSST) patients should be closely monitored for rejection and compliance with immunosuppression, claims a paper in the journal Cornea.
Dr A.Y. Ang et al., Cincinnati Eye Institute, Cincinnati, Ohio, USA, conducted a chart review of 222 eyes of 158 patients who underwent OSST at a single institution between 1998 and 2010. The group collected data on patient demographics, type of OSST procedure, duration of immunosuppression and rejection characteristics. The primary outcome measures were ocular surface stability and improvement in BCVA.
The most common indications for OSST were aniridia in 46.4% of patients, chemical/thermal injury in 22.1% and Stevens-Johnson syndrome in 12.2%. The most frequent procedures performed were keratolimbal allograft (KLAL) alone in 80.6% of patients and combined living-related conjunctival allograft (lr-CLAL)-KLAL in 11.3%.
Severe rejection was seen in 43 eyes, while low-grade rejection occurred in 26 eyes. At the final follow-up, 36.6% of eyes in the rejection group presented with a stable ocular surface, compared with 71.9% of eyes in the non-rejection group. Younger age, KLAL alone and noncompliance with immunosuppression were all factors that played a significant part in increasing the risk of rejection.
Please click here to read the abstract.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.